This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, your body may not process ergot derivatives properly.
What might happen:
Your blood levels of your ergot derivative may increase and cause chest pain; change in heartbeat; numbness and tingling of your hands, feet, or face; pain in your arms, legs, or lower back; or itching.
What you should do about this interaction:
Contact your healthcare professionals (e.g. doctor or pharmacist) as soon as possible about taking these two medicines together. They may already be aware of this drug interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Agenerase (amprenavir) Oral Solution US prescribing information. GlaxoSmithKline May, 2005.
2.Reyataz (atazanavir sulfate) US prescribing information. Bristol-Myers Squibb Company August, 2013.
3.Reyataz (atazanavir sulfate) Australian product information. Bristol-Myers Squibb Pharmaceuticals January 8, 2004.
4.Prezista (darunavir) US prescribing information. Tibotec Inc. November, 2013.
5.Lexiva (fosamprenavir calcium) US prescribing information. GlaxoSmithKline February, 2013.
6.Crixivan (indinavir sulfate) US prescribing information. Merck & Co., Inc. February, 2011.
7.Kaletra (lopinavir/ritonavir tablets) US prescribing information. Abbott Laboratories January, 2013.
8.Viracept (nelfinavir mesylate) US prescribing information. Agouron Pharmaceuticals, Inc. May, 2013.
9.Fortovase (saquinavir) US prescribing information. Roche Laboratories, Inc. December, 2004.
10.Invirase (saquinavir mesylate) US prescribing information. Roche Laboratories, Inc. February, 2012.
11.Aptivus (tipranavir) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. February, 2012.
12.Norvir (ritonavir) US prescribing information. Abbott Laboratories November, 2012.
13.Methergine (methylergonovine maleate) US prescribing information. Novartis Pharmaceuticals Corporation June, 2012.
14.Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP. Ergotism related to concurrent administration of ergotamine tartrate and indinavir. JAMA 1999 Mar 17;281(11):987.
15.Mortier E, Pouchot J, Vinceneux P, Lalande M. Ergotism related to interaction between nelfinavir and ergotamine. Am J Med 2001 May; 110(7):594.
16.Montero A, Giovannoni AG, Tvrde PL. Leg ischemia in a patient receiving ritonavir and ergotamine. Ann Intern Med 1999 Feb 16;130(4 Pt 1):329-30.
17.Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF. Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient. Antimicrob Agents Chemother 1997 May;41(5):1207.
18.Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D. Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir. Postgrad Med J 1999 Sep;75(887):546-7.
19.Liaudet L, Buclin T, Jaccard C, Eckert P. Drug points: severe ergotism associated with interaction between ritonavir and ergotamine. BMJ 1999 Mar 20;318(7186):771.
20.Pardo Rey C, Yebra M, Borrallo M, Vega A, Ramos A, Montero MC. Irreversible coma, ergotamine, and ritonavir. Clin Infect Dis 2003 Sep 1; 37(5):e72-3.
21.Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W. Cerebral ergotism under treatment with ergotamine and ritonavir. Neurology 2001 Aug 28;57(4):743-4.
22.Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F. Clinical ergotism induced by ritonavir. Scand J Infect Dis 2001; 33(10):788-9.
23.Gallo C, de la Fuente B, Garcia-Alcalde ML, Antuna A. Ergotism in a patient treated with ritonavir and ergotamine. Med Clin (Barc) 2002 Oct 26;119(14):558-9.
24.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.